Business Context and Reporting Period
This Form 8-K Current Report was filed by Brookdale Senior Living Inc. on February 26, 2020, regarding events occurring on February 24, 2020. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new independent director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation arrangements and governance structure.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- Class II Director Increase: The number of Class II directors increased from two to three.
- New Appointment: Jordan R. Asher, MD, MS, was appointed as a Class II independent director. His term is scheduled to expire at the 2020 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
The filing details the compensatory arrangements for the newly appointed director, Dr. Asher, which align with the Company's standard non-employee director compensation plan:
- Cash Retainer: $100,000 annual cash retainer, payable quarterly in arrears and pro-rated for partial service.
- Meeting Fees: $3,000 per Board meeting attended in excess of six meetings per calendar year; $2,000 per Committee meeting attended in excess of eight aggregate meetings per calendar year.
- Equity Awards:
- Annual grant of immediately vested stock with a grant date value of approximately $135,000 (typically granted in February for the prior year's service).
- Initial award of restricted shares with a grant value of approximately $100,000.
- Elective Compensation: Directors may elect to receive restricted stock units or shares under the Director Stock Purchase Program in lieu of up to 50% of quarterly cash compensation or the annual vested stock grant.
Dr. Asher has not yet been appointed to any Board committees. The filing states there are no transactions involving Dr. Asher requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the independence status of Dr. Asher under NYSE listing standards as confirmed by the Board.
- Confirm the pro-rata calculation for Dr. Asher's initial equity awards given his mid-year appointment.
- Review the Company's 2014 Omnibus Incentive Plan for specific vesting schedules and forfeiture conditions regarding the restricted stock units.
- Monitor future filings for Dr. Asher's committee assignments, as none were designated at the time of this report.